Active Ingredient History

  • Now
Bafetinib (NS-187) is an experimental cancer drug developed by Nippon Shinyaku and licensed to CytRx. It is an inhibitor of Lyn and Bcr-Abl. It reached phase II clinical trials in 2010.   Wikipedia

  • SMILES: CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc3ccc(C)c(Nc4nccc(n4)c5cncnc5)c3)C1
  • Mol. Mass: 576.63
  • ALogP: 5.39
  • ChEMBL Molecule:
More Chemistry
bafetinib | cns-9 | inno-406 | ns-187


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue